ERBB2 and small cell lung carcinoma: For “off‐targets,” such as MET amplification/overexpression, HER2 amplification, BRAF mutation, RET fusion, small cell lung cancer (SCLC) transformation, and so forth, there have been a lot of research and exploration in this field.